198 related articles for article (PubMed ID: 2698501)
1. [Polychemotherapy in multiple myeloma. The COMPA protocol].
Vázquez-Villegas V; Delgado Lamas JL; Romero-García F; Rodríguez-Carrillo J; Medina-Ruiz F
Rev Invest Clin; 1989; 41(4):345-50. PubMed ID: 2698501
[TBL] [Abstract][Full Text] [Related]
2. The addition of interferon or high dose cyclophosphamide to standard chemotherapy in the treatment of patients with multiple myeloma: phase III Eastern Cooperative Oncology Group Clinical Trial EST 9486.
Oken MM; Leong T; Lenhard RE; Greipp PR; Kay NE; Van Ness B; Keimowitz RM; Kyle RA
Cancer; 1999 Sep; 86(6):957-68. PubMed ID: 10491521
[TBL] [Abstract][Full Text] [Related]
3. [Results with the use of the M-2 protocol in plasmacytoma].
Ho AD; Wittkamp S; Theml H; Keilholz U; Hunstein W
Dtsch Med Wochenschr; 1986 May; 111(22):858-61. PubMed ID: 3754811
[TBL] [Abstract][Full Text] [Related]
4. Combination chemotherapy for multiple myeloma with melphalan, prednisone, cyclophosphamide, vincristine, and carmustine (BCNU) (M-2 protocol).
Tirelli U; Crivellari D; Carbone A; Veronesi A; Galligioni E; Trovò MG; Tumolo S; Grigoletto E
Cancer Treat Rep; 1982 Nov; 66(11):1971-3. PubMed ID: 6897205
[TBL] [Abstract][Full Text] [Related]
5. [Results of polychemotherapy (a VMCP/VCAP program) in multiple myeloma].
Wutke K; Anger G
Z Gesamte Inn Med; 1983 Dec; 38(23):630-3. PubMed ID: 6689459
[TBL] [Abstract][Full Text] [Related]
6. Comparison of melphalan and prednisone with vincristine, carmustine, melphalan, cyclophosphamide, and prednisone in the treatment of multiple myeloma: results of Eastern Cooperative Oncology Group Study E2479.
Oken MM; Harrington DP; Abramson N; Kyle RA; Knospe W; Glick JH
Cancer; 1997 Apr; 79(8):1561-7. PubMed ID: 9118039
[TBL] [Abstract][Full Text] [Related]
7. [Results of treatment of patients with advanced multiple myeloma with the vincristine-adriamycin-dexamethasone protocol].
Marisavljević D; Bosković D; Radosević N; Elezović I; Tomin D; Gotić M; Antunović P
Srp Arh Celok Lek; 1996; 124(11-12):292-6. PubMed ID: 9132962
[TBL] [Abstract][Full Text] [Related]
8. High dose chemotherapy followed by autologous haemopoietic stem cell transplant in multiple myeloma.
Kumar L; Raju GM; Ganessan K; Shawgi S; Menon H; Wadhwa J; Sharma A; Singh R; Kochupillai V
Natl Med J India; 2003; 16(1):16-21. PubMed ID: 12715951
[TBL] [Abstract][Full Text] [Related]
9. Hybrid chemotherapy consisting of cyclophosphamide, vincristine, procarbazine, prednisone, doxorubicin, bleomycin, and vinblastine (C-MOPP/ABV) as first-line treatment for patients with advanced Hodgkin disease.
Montoto S; Camós M; López-Guillermo A; Bosch F; Cervantes F; Blandé J; Esteve J; Cobo F; Nomdedeu B; Campo E; Montserrat E
Cancer; 2000 May; 88(9):2142-8. PubMed ID: 10813727
[TBL] [Abstract][Full Text] [Related]
10. Complete remission status before autologous stem cell transplantation is an important prognostic factor in patients with multiple myeloma undergoing upfront single autologous transplantation.
Kim JS; Kim K; Cheong JW; Min YH; Suh C; Kim H; Jo DY; Ryoo HM; Yoon SS; Lee JH;
Biol Blood Marrow Transplant; 2009 Apr; 15(4):463-70. PubMed ID: 19285634
[TBL] [Abstract][Full Text] [Related]
11. The therapeutic efficacy of VBCMP-M2 protocol in multiple myeloma.
Colović MD; Janković GM; Nikolov VS; Suvajdzić ND; Miletić VD
Haematologia (Budap); 1994; 26(2):91-6. PubMed ID: 7890267
[TBL] [Abstract][Full Text] [Related]
12. [Treatment of multiple myeloma using vincristine, cyclophosphamide, melphalan and prednisone (VCMP). Long-term results in 63 patients].
Bladé J; Urbano A; López Guillermo A; Rozman M; Rovira M; Montserrat E; Rozman C
Sangre (Barc); 1990 Apr; 35(2):93-7. PubMed ID: 2363100
[TBL] [Abstract][Full Text] [Related]
13. Complete response in multiple myeloma: clinical trial E9486, an Eastern Cooperative Oncology Group study not involving stem cell transplantation.
Kyle RA; Leong T; Li S; Oken MM; Kay NE; Van Ness B; Greipp PR
Cancer; 2006 May; 106(9):1958-66. PubMed ID: 16565956
[TBL] [Abstract][Full Text] [Related]
14. [Combination chemotherapy with vincristine, melphalan, CCNA, cyclophosphamide, prednisone in myeloma].
Le Loët X; Monconduit M; Menard JF; Deshayes P; Grobois B; Tanguy A; Prevost E; Piguet H
Rev Rhum Mal Osteoartic; 1984 May; 51(5):263-7. PubMed ID: 6740189
[TBL] [Abstract][Full Text] [Related]
15. Intermediate doses of melphalan and dexamethasone are better than vincristine, adriamycin, and dexamethasone (VAD) and polychemotherapy for the treatment of primary plasma cell leukemia.
Vela-Ojeda J; García-Ruiz Esparza MA; Rosas-Cabral A; Padilla-González Y; García-Chávez J; Tripp-Villanueva F; Sánchez-Cortés E; Ayala-Sánchez M; García-León LD; Montiel-Cervantes L; Rubio-Borja ME
Ann Hematol; 2002 Jul; 81(7):362-7. PubMed ID: 12185504
[TBL] [Abstract][Full Text] [Related]
16. [Recent therapy for refractory myeloma].
Togawa A
Rinsho Ketsueki; 1993 Apr; 34(4):450-4. PubMed ID: 8510332
[TBL] [Abstract][Full Text] [Related]
17. Therapy for multiple myeloma with alternating non-cross-resistant chemotherapy combinations: heterogeneity of tumor responsiveness.
Morstyn G; Schechter GP; Ihde DC; Carney DN; Eddy JL; Cohen MH; Minna JD; Bunn PA
Cancer Treat Rep; 1984 Dec; 68(12):1439-46. PubMed ID: 6391662
[TBL] [Abstract][Full Text] [Related]
18. [The efficacy of polychemotherapy programs in treating multiple myeloma patients].
Bessmel'tsev SS; Abdulkadyrov KM; Rukavitsyn OA
Ter Arkh; 1998; 70(7):46-9. PubMed ID: 9742636
[TBL] [Abstract][Full Text] [Related]
19. Allogeneic transplantation for multiple myeloma: further evidence for a GVHD-associated graft-versus-myeloma effect.
Le Blanc R; Montminy-Métivier S; Bélanger R; Busque L; Fish D; Roy DC; Kassis J; Boileau J; Lavallée R; Bélanger D; Letendre F; Hébert J; Sauvageau G; Perreault C; Roy J
Bone Marrow Transplant; 2001 Nov; 28(9):841-8. PubMed ID: 11781644
[TBL] [Abstract][Full Text] [Related]
20. [Combined treatment, polychemotherapy and amino-hydroxybutylidene-diphosphonate, of a patient with multiple myeloma: remission and long survival].
Attardo-Parrinello G; Merlini G; Crema F; Fiorentini ML; Mazzone A; Cotti-Piccinelli E
Medicina (Firenze); 1988; 8(3):318-20. PubMed ID: 3231044
[No Abstract] [Full Text] [Related]
[Next] [New Search]
